Cordis continues to expand interventional cardiology portfolio with radial offering

Over 560 Pennsylvania Auctions End Today - Bid Now
Over 2450 Total Lots Up For Auction at Seven Locations - Over 650 Oklahoma Auctions End Tomorrow 06/23 - Bid Now, UT 06/24, CA 06/25, NJ 06/28, NJ Cleansweep 06/29, MN 06/30, NY 07/06

Cordis continues to expand interventional cardiology portfolio with radial offering

Press releases may be edited for formatting or style | May 14, 2019 Cardiology
DUBLIN, Ohio, May 14, 2019 /PRNewswire/ -- Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures.

The transradial approach uses the radial artery in the wrist to access the body's arterial system, instead of using the femoral artery in the groin. This launch marks the beginning of a global radial product portfolio rollout to reach cardiovascular patients worldwide. The Cordis RADIAL 360 portfolio is composed of:

RAIN Sheath™ Transradial Thin-Walled Introducer

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

RAILWAY™ Sheathless Access System
RBL-TG™ and RBL-JK™ Universal Shapes for the INFINITI® and SUPER TORQUE® PLUS Diagnostic Catheters
ZEPHYR® Vascular Compression Band

Compared to a femoral access approach, TRA in the wrist can offer fewer bleeding complications, faster post-procedure mobility, improved patient comfort, and faster patient discharge resulting in reduced in-hospital costs.1,2,3 TRA use in the U.S. is currently estimated to be approximately 30 percent of overall percutaneous coronary interventions and growing.4 In ST-Segment Elevation Myocardial Infarction (STEMI) patients alone, which represent the most severe type of heart attack, TRA use increased from 2 percent in 2009 to 23 percent in 2015.5 In Europe, Japan, China and Canada, TRA is currently used in the majority of cases.6,7

"The transradial approach has been an important advancement in how we treat coronary artery disease because of both the patient benefits, and the advantages realized by the hospital in terms of procedure flow and economics," said Kintur Sanghvi, MD, FACC, FSCAI, associate medical director of Interventional Cardiology at Deborah Heart & Lung Center in Browns Mills, NJ and inventor of the RAILWAY™ System. "We look to the industry to help us advance the tools available for this technique, which Cordis has done with the introduction of the RADIAL 360 portfolio. In my experience with the RAILWAY™ System, I see the clear advantage of downsizing the radial access by up to 2 French, a benefit that I'm unable to achieve with anything else that's currently on the market."

In addition to the RAILWAY™ System, which received CE Mark in March 2017 and was FDA cleared in April 2018, the portfolio features the RAIN Sheath™ Transradial Introducer, which offers an ultra-low profile design, lubricious hydrophilic coating, and proprietary KINK RECOVERY TECHNOLOGY™ that enables the sheath to maintain lumen patency throughout the procedure, even after a kink occurs.

You Must Be Logged In To Post A Comment